RxSight, Inc.
Nasdaq: RXSTOphthalmic Goods · Entity-resolved by Clous
CIK0001111485
TickerRXST
ExchangeNasdaq
SIC3851
StateDE
FY end12-31
Key financials
RevenueFY2025-12-31
$134.48M
-3.9% YoY
Net IncomeFY2025-12-31
-$38.94M
-41.8% YoY
Total AssetsFY2025-12-31
$311.81M
-2.1% YoY
EquityFY2025-12-31
$275.68M
-2.0% YoY
Shares OutstandingFY2025-12-31
41.27M
—
Operating Cash FlowFY2025-12-31
-$15.51M
+8.5% YoY
Market
Market
RXSTClose price
$4.71
Market cap
$194.98M
delayed EOD · as of 2026-06-18
Short interest & fails
Fails-to-deliver
SEC CNS fails · semi-monthly21
shares failed · 2026-05-27
2026-05-2721 sh$5.99
2026-04-29766 sh$7.17
2026-04-23502 sh$7.40
2026-04-22576 sh$7.09
2026-04-20102 sh$7.61
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
The filing consists mainly of XBRL taxonomy references and dates, without readable narrative or financial details about RxSight’s operations or results.
What it means
No substantive information is disclosed; the filing provides no insight into the company’s performance or condition.
What to watch
Monitor future filings for actual financial statements and management discussion.
Generated from public filings · not investment advice
| Concept | FY2022-12-31 | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Revenue | $49.01M | $89.08M | $139.93M | $134.48M | -3.9% | 100% |
| Net Income | -$66.76M | -$48.61M | -$27.46M | -$38.94M | -41.8% | -29% |
| Total Assets | $150.16M | $182.55M | $318.56M | $311.81M | -2.1% | 232% |
| Equity | $89.9M | $160.36M | $281.24M | $275.68M | -2.0% | 205% |
| Operating Cash Flow | -$58.85M | -$41.59M | -$16.95M | -$15.51M | +8.5% | -12% |
| Shares Outstanding | — | — | — | 41.27M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001111485